SysMedPD · Project

Precision Drug Discovery Platform for Parkinson's Disease With Mitochondrial Problems

healthPrototypeTRL 4Thin data (2/5)

Imagine your brain cells have tiny power plants called mitochondria — in some Parkinson's patients, those power plants are failing. This project built a complete drug testing pipeline: they grew patients' own brain cells in a dish using stem cells, ran them through miniaturised lab-on-a-chip devices, and used computer models to predict which drugs could rescue those failing power plants. The goal was to shortcut years of trial-and-error by screening compounds against personalised cell models before ever reaching a clinical trial. They focused on the estimated 1-2 million people worldwide whose Parkinson's is specifically linked to mitochondrial problems.

By the numbers

1-2 million

People worldwide estimated to suffer from Parkinson's with mitochondrial dysfunction

EUR 5,999,990

EU funding invested in developing this platform

Consortium partners across 5 countries

Industry partners including SMEs in the consortium

Total project deliverables produced

The business problem

What needed solving

Parkinson's drug development has extremely high failure rates because researchers lack reliable ways to test compounds on human brain cells before expensive clinical trials. The estimated 1-2 million patients with mitochondria-linked Parkinson's have no targeted treatments because current screening tools cannot distinguish this patient subgroup or predict which drugs will work for them specifically.

The solution

What was built

The project delivered a miniaturised metabolomics platform with sample transport capability, a complete computational model of brain metabolism, mitochondrial molecular network reconstructions, a metabolomics platform for mitochondrial dysfunction, and an industrial-quality 3D microfluidic cell culture product for growing patient-derived dopaminergic neurons. Together these form a preclinical drug screening pipeline from patient cells to computer-predicted drug targets.

Audience

Who needs this

Pharma companies with Parkinson's or neurodegenerative disease pipelinesBiotech startups developing mitochondria-targeting therapiesDiagnostics companies building patient stratification tests for neurological diseasesMicrofluidics and organ-on-chip manufacturers expanding into neuroscienceContract research organisations (CROs) offering iPSC-based drug screening services

Business applications

Who can put this to work

Pharmaceutical & Biotech

enterprise

Target: Mid-to-large pharma companies with neurodegenerative disease pipelines

If you are a pharma company struggling with high failure rates in Parkinson's drug trials — this project developed a personalised iPSC-based screening platform combined with computational models of dopaminergic neuron metabolism. It lets you test lead compounds on patient-derived brain cells in 3D microfluidic culture before committing to expensive animal studies. The consortium included 3 industry partners and built validated metabolomics and computational tools over 5 years.

Diagnostics & Precision Medicine

mid-size

Target: Companies developing companion diagnostics or patient stratification tools

If you are a diagnostics company looking to enter the Parkinson's market — this project created computational models that can stratify idiopathic Parkinson's patients by their degree of mitochondrial dysfunction. This means you could develop a diagnostic test that identifies which patients would respond to mitochondria-targeting therapies, a growing segment estimated at 1-2 million people worldwide. The metabolomics platform they built could form the basis for a clinical biomarker assay.

Lab Equipment & Microfluidics

any

Target: Companies producing cell culture systems or organ-on-chip platforms

If you are a lab equipment manufacturer expanding into neuroscience applications — this project developed an industrial-quality 3D microfluidic cell culture product specifically designed for iPSC-derived dopaminergic neurons. This is a ready-to-adapt product concept for companies already making organ-on-chip devices. The miniaturised metabolomics platform with integrated sample transport could also be licensed or co-developed for commercial distribution.

Frequently asked

Quick answers

What would it cost to license or use this technology?

The project was funded with EUR 5,999,990 in EU contribution across 9 partners over 5 years. Licensing terms would need to be negotiated directly with the consortium, likely led by Universiteit Leiden. As an RIA (Research and Innovation Action), IP is typically held by the partners who generated it, so costs would depend on which specific deliverable you need.

Can this scale to industrial pharmaceutical screening?

The project specifically aimed for industrial quality in its 3D microfluidic cell culture product for screening lead compounds. The miniaturised metabolomics platform was designed with a storage device for sample transport, suggesting portability and scalability were considered. However, this remains at preclinical stage and would require further validation for industrial-scale drug screening campaigns.

What is the IP situation and how can I license this?

As a Horizon 2020 RIA project, intellectual property is owned by the partners who created it. With 3 industry partners and 3 SMEs in the consortium, some IP may already be commercially oriented. Contact the coordinator at Universiteit Leiden or the industrial partners for licensing discussions.

Is this ready for clinical use or still in research phase?

This is a preclinical research platform. The project identified candidate neuroprotectants and built screening tools, but no clinical trials were part of this project. Any drug candidates emerging would still need years of clinical development before reaching patients.

How does this integrate with existing drug discovery workflows?

The platform was designed to slot into early-stage drug discovery: computational models prioritise targets, iPSC-derived neurons provide human-relevant cell models, and the 3D microfluidic system enables morphological and bioanalytical screening. The metabolomics platform can characterise compound effects. These tools complement rather than replace existing pipelines.

What regulatory pathway would apply?

The screening platform itself is a research tool and does not require regulatory approval for use in R&D. However, any drug candidates identified through the platform would follow standard EMA/FDA clinical trial pathways. The diagnostics application (patient stratification) would require IVD certification if commercialised.

Is ongoing support or collaboration available?

The project ended in November 2020, but the consortium partners — particularly the 3 industry-focused SMEs and Universiteit Leiden — likely continue related research. Based on available project data, the computational models and metabolomics platforms were fully delivered and could be accessed through collaboration agreements.

Consortium

Who built it

The SysMedPD consortium brings together 9 partners from 5 countries (Germany, Ireland, Luxembourg, Netherlands, UK), with a healthy 33% industry ratio — 3 of the 9 partners are from industry, all classified as SMEs. This mix of 6 universities providing deep scientific expertise and 3 agile SMEs suggests the project was designed with eventual commercialisation in mind. The coordinator, Universiteit Leiden in the Netherlands, is a well-established research university. The presence of 3 SME partners is notable for a preclinical project and indicates that microfluidics, metabolomics, or computational modelling components may already have commercial development pathways. The EUR 5,999,990 budget spread across 9 partners over 5 years represents substantial investment in platform development.

UNIVERSITEIT LEIDENCoordinator · NL
MIMETAS BVparticipant · NL
UNIVERSITATSKLINIKUM SCHLESWIG-HOLSTEINthirdparty · DE
EURICE EUROPEAN RESEARCH AND PROJECT OFFICE GMBHparticipant · DE
NATIONAL UNIVERSITY OF IRELAND MAYNOOTHparticipant · IE
UNIVERSITE DU LUXEMBOURGparticipant · LU
UNIVERSITY COLLEGE LONDONparticipant · UK
UNIVERSITAET zu LUEBECKparticipant · DE
KHONDRION BVparticipant · NL

How to reach the team

Universiteit Leiden (Netherlands) — contact through university technology transfer office or project website

Order a report on this consortium See UNIVERSITEIT LEIDEN profile →

Next steps

Talk to the team behind this work.

Want to explore licensing the metabolomics platform or computational models from SysMedPD? SciTransfer can connect you directly with the right consortium partner. Contact us for a detailed briefing.

Order a report on this topic More in Health & Biomedical